Pioneering Precision Therapies in Liver Oncology

Targeted Therapy Through Innovation

Our therapy is built on a breakthrough gene delivery platform licensed from Hovione, which enables precise steering of adeno-associated virus (AAV) vectors directly to cancerous liver cells. This specificity significantly enhances therapeutic efficacy, having the potential to reduce side effects, and enables more efficient, sustainable manufacturing – a critical advancement over current gene therapy standards. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and represents a major global health challenge. Each year, approximately 900,000 new cases are diagnosed worldwide. Despite advancements in medical research, the 5-year survival rate remains alarmingly low at just 21%. These figures underline the urgent need for more effective and targeted treatment options, particularly for patients who are diagnosed at an advanced stage or are not eligible for surgical interventions.